Tharimmune (THAR) Competitors $5.83 -0.22 (-3.70%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. ARTV, RPTX, ZIVO, MNOV, IMMX, INMB, ANL, GANX, GNTA, and CUEShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Artiva Biotherapeutics (ARTV), Repare Therapeutics (RPTX), ZIVO Bioscience (ZIVO), MediciNova (MNOV), Immix Biopharma (IMMX), INmune Bio (INMB), Adlai Nortye (ANL), Gain Therapeutics (GANX), Genenta Science (GNTA), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Artiva Biotherapeutics Repare Therapeutics ZIVO Bioscience MediciNova Immix Biopharma INmune Bio Adlai Nortye Gain Therapeutics Genenta Science Cue Biopharma Artiva Biotherapeutics (NASDAQ:ARTV) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Do insiders & institutionals hold more shares of ARTV or THAR? 1.2% of Tharimmune shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ARTV or THAR? In the previous week, Tharimmune had 6 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Tharimmune and 4 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.29 beat Tharimmune's score of 0.29 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ARTV or THAR more profitable? Artiva Biotherapeutics' return on equity of -42.60% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -42.60% -37.76% Tharimmune N/A -1,239.20%-365.06% Which has higher earnings & valuation, ARTV or THAR? Tharimmune has lower revenue, but higher earnings than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K309.28-$65.37MN/AN/ATharimmuneN/AN/A-$12.20M-$6.10-0.96 Do analysts recommend ARTV or THAR? Artiva Biotherapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 437.12%. Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 191.80%. Given Artiva Biotherapeutics' higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryArtiva Biotherapeutics beats Tharimmune on 7 of the 12 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.16M$3.07B$5.75B$9.76BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-0.9621.0131.4526.44Price / SalesN/A351.99428.19154.88Price / CashN/A44.7137.7559.42Price / Book83.238.0210.536.59Net Income-$12.20M-$53.98M$3.27B$265.92M7 Day Performance23.43%-1.11%1.04%0.23%1 Month Performance334.78%5.35%5.74%2.19%1 Year Performance108.07%9.17%50.88%21.20% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.4552 of 5 stars$5.83-3.7%$17.00+191.8%+107.9%$31.16MN/A-0.962Gap UpARTVArtiva Biotherapeutics3.1537 of 5 stars$2.71-2.9%$17.00+527.3%-71.1%$66.21M$250K0.0081Positive NewsGap UpRPTXRepare Therapeutics2.8239 of 5 stars$1.54+0.3%$4.50+193.2%-45.0%$65.94M$53.48M-0.59180Positive NewsZIVOZIVO Bioscience0.2274 of 5 stars$17.20-4.7%N/A+57.5%$65.65M$15.85K-3.5210News CoverageGap DownMNOVMediciNova2.2237 of 5 stars$1.31+0.8%$7.00+434.4%-2.2%$64.25M$1M-5.2410Analyst ForecastGap UpIMMXImmix Biopharma3.3219 of 5 stars$2.19flat$7.00+219.6%+3.2%$63.15MN/A-2.849INMBINmune Bio2.0048 of 5 stars$2.36-1.7%$18.40+679.7%-69.4%$62.74M$50K-0.9510Positive NewsANLAdlai Nortye1.6659 of 5 stars$1.70-0.3%$9.00+431.0%-43.9%$62.55MN/A0.00127Positive NewsGANXGain Therapeutics2.1895 of 5 stars$1.73+2.4%$7.80+350.9%+41.4%$62.19MN/A-2.7520News CoverageAnalyst RevisionGNTAGenenta Science2.3522 of 5 stars$3.40-0.3%$25.00+635.5%-6.1%$62.17MN/A0.007News CoverageCUECue Biopharma2.6104 of 5 stars$0.81-0.9%N/A+14.5%$62.13M$9.29M-1.4460 Related Companies and Tools Related Companies Artiva Biotherapeutics Competitors Repare Therapeutics Competitors ZIVO Bioscience Competitors MediciNova Competitors Immix Biopharma Competitors INmune Bio Competitors Adlai Nortye Competitors Gain Therapeutics Competitors Genenta Science Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access